Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer

Kamat, Ashish M.Lerner, SethBlack, PeterBellmunt, JoaquimDinney, ColinHahn, Noah M.O’Donnell, MichaelQuale, Diane Z.2017-11-212017Kamat, Ashish M., Seth Lerner, Peter Black, Joaquim Bellmunt, Colin Dinney, Noah M. Hahn, Michael O’Donnell, and Diane Z. Quale. 2017. “Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer.” Bladder Cancer (Amsterdam, Netherlands) 3 (3): 145-146. doi:10.3233/BLC-170118. http://dx.doi.org/10.3233/BLC-170118.http://nrs.harvard.edu/urn-3:HUL.InstRepos:34375110en-USOnce BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder CancerJournal Article2017-11-2110.3233/BLC-170118